NABNEC
22 Dec 2020
Trial Summary
The primary purpose of this trial is to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide chemotherapy for the treatment of gastrointestinal neuroendocrine carcinomas (NECs).
Acronym:
NABNEC
ACTRN/NCT /ethics:
ACTRN12616000958482; Ethics 163.17
Scientific title:
A randomised phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas.
Sponsor / Cooperative group:
Australasian Gastro-Intestinal Trials Group (AGITG)
Trial & Patient Characteristics
| Cancer Type | Neuroendocrine |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2016-08-19 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Professor Chris Karapetis |
| Recruitment Status | Recruiting |